Join Growin Stock Community!

神隆1789.TW Overview

TW StockBiotech. & Medical
(No presentation for 1789)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

神隆（1789）Overall Performance

神隆（1789）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

神隆（1789） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

神隆（1789）Key Information

神隆（1789）Profile

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

神隆（1789）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.24
PE Ratio (TTM)
86.03
Forward PE
43.75
PS Ratio (TTM)
5.20
PB Ratio
1.51
Price-to-FCF
10.97
METRIC
VALUE
vs. INDUSTRY
Gross Margin
35.73%
Net Margin
6.05%
Revenue Growth (YoY)
-8.62%
Profit Growth (YoY)
-17.40%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-3.54%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.24
PE Ratio (TTM)
86.03
Forward PE
43.75
PS Ratio (TTM)
5.20
PB Ratio
1.51
Price-to-FCF
10.97
Gross Margin
35.73%
Net Margin
6.05%
Revenue Growth (YoY)
-8.62%
Profit Growth (YoY)
-17.40%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-3.54%
default symbol

1789

神隆

21.00D

-3.33%

(-0.03)

  • When is 1789's latest earnings report released?

    The most recent financial report for 神隆 (1789) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1789's short-term business performance and financial health. For the latest updates on 1789's earnings releases, visit this page regularly.

  • Where does 1789 fall in the P/E River chart?

    According to historical valuation range analysis, 神隆 (1789)'s current price-to-earnings (P/E) ratio is 61.45, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1789?

    According to the latest financial report, 神隆 (1789) reported an Operating Profit of -19.62M with an Operating Margin of -2.72% this period, representing a decline of 161.62% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1789's revenue growth?

    In the latest financial report, 神隆 (1789) announced revenue of 721.5M, with a Year-Over-Year growth rate of -0.38%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1789 have?

    At the end of the period, 神隆 (1789) held Total Cash and Cash Equivalents of 2.85B, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1789 go with three margins increasing?

    In the latest report, 神隆 (1789) did not achieve the “three margins increasing” benchmark, with a gross margin of 29.91%%, operating margin of -2.72%%, and net margin of 2.14%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1789's profit trajectory and future growth potential.

  • Is 1789's EPS continuing to grow?

    According to the past four quarterly reports, 神隆 (1789)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1789?

    神隆 (1789)'s Free Cash Flow (FCF) for the period is -26.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.